Most cancers facilities are re-evaluating their relationships with well being care firms, together with when, if ever, medical doctors and researchers ought to serve on company boards. Listed here are some hospital executives and most cancers researchers who sit on the boards of publicly traded firms, in twin roles that will elevate questions on conflicts of curiosity.
Dr. Laurie H. Glimcher
President and chief executive of the Dana-Farber Most cancers Institute, Boston
Firm: Dr. Glimcher sits on the boards of the British drugmaker GlaxoSmithKline and Waters Corp., a laboratory tools and software program firm.
Exterior Compensation: Dr. Glimcher joined the board of GlaxoSmithKline in September of 2017; she acquired $101,00zero in whole compensation from the corporate that yr, plus compensation of $285,440 from Waters that yr.
Dr. Gary Gilliland
President and director of the Fred Hutchinson Most cancers Analysis Heart, Seattle
Firm: Dr. Gilliland serves on the board of LabCorp, a blood testing firm.
Exterior Compensation: Dr. Gilliland acquired $269,948 in money and inventory from LabCorp in 2017.
Mary C. Beckerle
Chief executive of the Huntsman Most cancers Institute on the College of Utah, Salt Lake Metropolis
Firm: Dr. Beckerle is on the board of the well being care large Johnson & Johnson and the Huntsman Company, a chemical producer.
Dr. Craig B. Thompson
Chief executive of Memorial Sloan Kettering Most cancers Heart, New York
Firm: Dr. Thompson resigned in October from the boards of the drug maker Merck and of Charles River Laboratories, which assists in early analysis.
Exterior Compensation: In 2017, Dr. Thompson acquired $300,00zero in compensation from Merck. He acquired $285,zero50 in money and firm inventory from Charles River in 2017.
Deputy director for core applied sciences of the Sloan Kettering Institute, the analysis arm of Memorial Sloan Kettering Most cancers Heart, New York
Firm: President, chief executive and chief scientific officer at AngioGenex, a tiny, publicly traded biotech.
Exterior Compensation: He took no wage from AngioGenex in 2017, however he owns practically 9 % of the corporate in inventory or inventory choices.
Dr. Charles L. Sawyers
Chair of the human oncology and pathogenesis program at Memorial Sloan Kettering Most cancers Heart, New York
Firm: Member of the board of Novartis, the Swiss pharmaceutical firm. Founding father of a number of firms, together with ORIC Prescribed drugs, a personal most cancers start-up. (His wage at Memorial Sloan Kettering is paid by the Howard Hughes Medical Institute.)
Exterior Compensation: Dr. Sawyers acquired whole compensation in 2017 of about $360,00zero from Novartis.
SOURCE: COMPANY FILINGS; EQUILAR.